Molecular Pathobiology of the Cerebrovasculature in Aging and in Alzheimers Disease Cases With Cerebral Amyloid Angiopathy.

Alzheimers disease cerebral amyloid angiopathy cerebrovasculature endothelial cells mass spectrometry mural cells perivascular cells proteomics

Journal

Frontiers in aging neuroscience
ISSN: 1663-4365
Titre abrégé: Front Aging Neurosci
Pays: Switzerland
ID NLM: 101525824

Informations de publication

Date de publication:
2021
Historique:
received: 26 01 2021
accepted: 10 03 2021
entrez: 3 6 2021
pubmed: 4 6 2021
medline: 4 6 2021
Statut: epublish

Résumé

Cerebrovascular dysfunction and cerebral amyloid angiopathy (CAA) are hallmark features of Alzheimer's disease (AD). Molecular damage to cerebrovessels in AD may result in alterations in vascular clearance mechanisms leading to amyloid deposition around blood vessels and diminished neurovascular-coupling. The sequelae of molecular events leading to these early pathogenic changes remains elusive. To address this, we conducted a comprehensive in-depth molecular characterization of the proteomic changes in enriched cerebrovessel fractions isolated from the inferior frontal gyrus of autopsy AD cases with low (85.5 ± 2.9 yrs) vs. high (81 ± 4.4 yrs) CAA score, aged-matched control (87.4 ± 1.5 yrs) and young healthy control (47 ± 3.3 yrs) cases. We employed a 10-plex tandem isobaric mass tag approach in combination with our ultra-high pressure liquid chromatography MS/MS (Q-Exactive) method. Enriched cerebrovascular fractions showed very high expression levels of proteins specific to endothelial cells, mural cells (pericytes and smooth muscle cells), and astrocytes. We observed 150 significantly regulated proteins in young vs. aged control cerebrovessels. The top pathways significantly modulated with aging included chemokine, reelin, HIF1α and synaptogenesis signaling pathways. There were 213 proteins significantly regulated in aged-matched control vs. high CAA cerebrovessels. The top three pathways significantly altered from this comparison were oxidative phosphorylation, Sirtuin signaling pathway and TCA cycle II. Comparison between low vs. high CAA cerebrovessels identified 84 significantly regulated proteins. Top three pathways significantly altered between low vs. high CAA cerebrovessels included TCA Cycle II, Oxidative phosphorylation and mitochondrial dysfunction. Notably, high CAA cases included more advanced AD pathology thus cerebrovascular effects may be driven by the severity of amyloid and Tangle pathology. These descriptive proteomic changes provide novel insights to explain the age-related and AD-related cerebrovascular changes contributing to AD pathogenesis. Particularly, disturbances in energy bioenergetics and mitochondrial biology rank among the top AD pathways altered in cerebrovessels. Targeting these failed mechanisms in endothelia and mural cells may provide novel disease modifying targets for developing therapeutic strategies against cerebrovascular deterioration and promoting cerebral perfusion in AD. Our future work will focus on interrogating and validating these novel targets and pathways and their functional significance.

Identifiants

pubmed: 34079449
doi: 10.3389/fnagi.2021.658605
pmc: PMC8166206
doi:

Types de publication

Journal Article

Langues

eng

Pagination

658605

Subventions

Organisme : NIA NIH HHS
ID : R01 AG041971
Pays : United States

Informations de copyright

Copyright © 2021 Ojo, Reed, Crynen, Vallabhaneni, Evans, Shackleton, Eisenbaum, Ringland, Edsell, Mullan, Crawford and Bachmeier.

Déclaration de conflit d'intérêts

JR was employed by company Boehringer Ingelheim Pharmaceuticals, Inc. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Neural Dev. 2018 May 1;13(1):7
pubmed: 29712572
Jpn J Psychiatry Neurol. 1991 Sep;45(3):661-5
pubmed: 1800813
J Biol Chem. 2007 Apr 13;282(15):10873-80
pubmed: 17303576
Neurobiol Dis. 2015 Oct;82:593-606
pubmed: 26311408
Nucleic Acids Res. 2016 Jan 4;44(D1):D447-56
pubmed: 26527722
Neuron. 2009 Aug 13;63(3):287-303
pubmed: 19679070
Nat Med. 2020 May;26(5):769-780
pubmed: 32284590
J Cereb Blood Flow Metab. 2016 Jan;36(1):216-27
pubmed: 25757756
Acta Neuropathol. 2021 Jan;141(1):1-24
pubmed: 33098484
Neurosci Lett. 1988 Sep 12;91(3):259-64
pubmed: 2972943
Ann Neurol. 2000 Jun;47(6):739-47
pubmed: 10852539
Neurol Res. 2003 Sep;25(6):642-51
pubmed: 14503019
Acta Neuropathol. 2007 Jan;113(1):13-21
pubmed: 17021755
Nature. 2020 May;581(7806):71-76
pubmed: 32376954
Curr Pharm Des. 2015;21(1):114-20
pubmed: 25330331
JAMA. 1997 Mar 12;277(10):813-7
pubmed: 9052711
Ann Neurol. 1991 Nov;30(5):637-49
pubmed: 1763890
J Mal Vasc. 2002 Jul;27 Spec No:S13-8
pubmed: 12587216
Science. 2019 Jul 19;365(6450):
pubmed: 31221773
Cold Spring Harb Perspect Med. 2012 Nov 01;2(11):
pubmed: 23125202
Brain. 2012 Dec;135(Pt 12):3749-56
pubmed: 23204143
J Stroke Cerebrovasc Dis. 2008 Sep;17(5):303-11
pubmed: 18755411
Proc Natl Acad Sci U S A. 2013 May 7;110(19):E1807-16
pubmed: 23620513
Acta Neuropathol Commun. 2018 Jun 4;6(1):46
pubmed: 29860944
Neuron. 2020 Mar 18;105(6):975-991.e7
pubmed: 31926610
J Neurol Neurosurg Psychiatry. 2014 Mar;85(3):300-5
pubmed: 24163429
BMC Med. 2014 Nov 11;12:130
pubmed: 25385322
J Alzheimers Dis. 2011;24(2):315-25
pubmed: 21263194
Neuron. 2014 Feb 19;81(4):740-54
pubmed: 24559670
Vasc Health Risk Manag. 2008;4(2):363-81
pubmed: 18561512
Ann Neurol. 1995 Aug;38(2):254-9
pubmed: 7654074
Bioinformatics. 2014 Feb 15;30(4):523-30
pubmed: 24336805
CNS Neurol Disord Drug Targets. 2009 Mar;8(1):50-64
pubmed: 19275636
J Neuropathol Exp Neurol. 2008 Sep;67(9):842-56
pubmed: 18716559
J Neuroinflammation. 2011 Sep 09;8:115
pubmed: 21906275
J Neuropathol Exp Neurol. 1998 Apr;57(4):353-9
pubmed: 9600229
Neurobiol Aging. 2000 Mar-Apr;21(2):153-60
pubmed: 10867200
Neurobiol Dis. 2019 Jan;121:230-239
pubmed: 30308244
Oncotarget. 2017 Jul 4;8(27):44477-44489
pubmed: 28574812
Front Neuroenergetics. 2010 May 21;2:
pubmed: 20725515
J Neurosci. 2005 Nov 30;25(48):11165-74
pubmed: 16319316
Eur Radiol. 2016 Feb;26(2):506-14
pubmed: 26040647
Jpn J Psychiatry Neurol. 1991 Sep;45(3):671-6
pubmed: 1800815
Ann Med. 1989;21(2):99-102
pubmed: 2527522
Neurobiol Aging. 2013 Apr;34(4):1018-31
pubmed: 23084084
J Neurosci. 2003 Aug 27;23(21):7889-96
pubmed: 12944519
Neurol Res. 2003 Sep;25(6):661-4
pubmed: 14503021
BMC Neurol. 2020 Aug 27;20(1):317
pubmed: 32854643
J Neurosci. 2005 Mar 16;25(11):2803-10
pubmed: 15772340
Science. 2012 Mar 23;335(6075):1503-6
pubmed: 22323736
Acta Neuropathol. 2002 May;103(5):481-7
pubmed: 11935264
Am J Pathol. 1964 Feb;44:269-97
pubmed: 14119171
J Alzheimers Dis. 2006 Mar;9(1):51-8
pubmed: 16627934
Neurobiol Aging. 2007 Jul;28(7):977-86
pubmed: 16782234
Neurodegener Dis. 2018;18(1):49-56
pubmed: 29402847
Neurol Res. 2004 Jul;26(5):525-39
pubmed: 15265270
Mt Sinai J Med. 2010 Jan-Feb;77(1):82-102
pubmed: 20101718
Ann N Y Acad Sci. 2000 Apr;903:176-9
pubmed: 10818505
Brain. 2014 Jan;137(Pt 1):255-67
pubmed: 24271328
Acta Neuropathol. 2000 Oct;100(4):395-402
pubmed: 10985698
Brain. 2018 Jul 1;141(7):2032-2046
pubmed: 30053174
Stroke. 1995 May;26(5):743-8
pubmed: 7740560
J Neurol Sci. 2004 Nov 15;226(1-2):13-7
pubmed: 15537512
J Neuropathol Exp Neurol. 2008 Apr;67(4):261-70
pubmed: 18379441
Curr Alzheimer Res. 2007 Apr;4(2):191-7
pubmed: 17430246
BMC Med. 2014 Nov 11;12:218
pubmed: 25385509
Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):486-510
pubmed: 15747152
J Neuropathol Exp Neurol. 2003 Dec;62(12):1287-301
pubmed: 14692704
J Cereb Blood Flow Metab. 2017 Mar;37(3):1120-1136
pubmed: 27339263
Alzheimer Dis Assoc Disord. 1999 Oct-Dec;13 Suppl 3:S115-23
pubmed: 10609690
Nature. 2012 May 16;485(7399):512-6
pubmed: 22622580
ASN Neuro. 2020 Jan-Dec;12:1759091420914768
pubmed: 32241177
Ultrastruct Pathol. 1994 May-Jun;18(3):333-48
pubmed: 8066824
J Neuroimmunol. 2002 Mar;124(1-2):83-92
pubmed: 11958825
Pharmacol Ther. 1996;72(3):193-214
pubmed: 9364575
Int J Alzheimers Dis. 2011;2011:810981
pubmed: 22028984
Neuropathol Appl Neurobiol. 2004 Feb;30(1):46-56
pubmed: 14720176
Neurol Res. 1993 Jun;15(3):146-53
pubmed: 8103579
Neurobiol Dis. 2021 Mar;150:105237
pubmed: 33383188
BMJ. 2001 Jun 16;322(7300):1447-51
pubmed: 11408299
Neurobiol Aging. 1988 Jul-Aug;9(4):339-49
pubmed: 3263583
J Cereb Blood Flow Metab. 2004 Mar;24(3):334-42
pubmed: 15091114
J Clin Med. 2019 May 10;8(5):
pubmed: 31083442
Science. 2010 Dec 24;330(6012):1774
pubmed: 21148344
Neuropathol Appl Neurobiol. 2017 Oct;43(6):492-504
pubmed: 27543695
Cell Mol Neurobiol. 2016 Mar;36(2):167-79
pubmed: 26898552
J Alzheimers Dis. 2018;63(1):35-52
pubmed: 29614675
J Neuropathol Exp Neurol. 2008 Oct;67(10):923-32
pubmed: 18800015
Prog Neurobiol. 2001 Aug;64(6):575-611
pubmed: 11311463
J Neurosci. 2005 Jan 19;25(3):629-36
pubmed: 15659599
N Engl J Med. 2014 Jan 23;370(4):322-33
pubmed: 24450891
Mol Neurodegener. 2018 Oct 4;13(1):52
pubmed: 30286791
Neurology. 2013 Jul 16;81(3):292-300
pubmed: 23858411
Neurologist. 2018 Mar;23(2):47-50
pubmed: 29494434
Dement Neuropsychol. 2017 Oct-Dec;11(4):364-370
pubmed: 29354216
Sci Transl Med. 2011 Jun 29;3(89):89ra57
pubmed: 21715678
J Neuropathol Exp Neurol. 2013 Jul;72(7):708-15
pubmed: 23771217
Stroke. 2004 Nov;35(11 Suppl 1):2623-7
pubmed: 15375298
Neurodegener Dis. 2010;7(1-3):116-21
pubmed: 20173340
J Neuropathol Exp Neurol. 1997 Feb;56(2):165-70
pubmed: 9034370
Stroke. 2004 Apr;35(4):1010-7
pubmed: 15001795

Auteurs

Joseph O Ojo (JO)

Roskamp Institute, Sarasota, FL, United States.
James A. Haley Veterans' Hospital, Tampa, FL, United States.
The Open University, Milton Keynes, United Kingdom.

Jon M Reed (JM)

Roskamp Institute, Sarasota, FL, United States.
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, United States.

Gogce Crynen (G)

Roskamp Institute, Sarasota, FL, United States.

Prashanthi Vallabhaneni (P)

Roskamp Institute, Sarasota, FL, United States.

James Evans (J)

Roskamp Institute, Sarasota, FL, United States.

Benjamin Shackleton (B)

Roskamp Institute, Sarasota, FL, United States.
The Open University, Milton Keynes, United Kingdom.

Maximillian Eisenbaum (M)

Roskamp Institute, Sarasota, FL, United States.
The Open University, Milton Keynes, United Kingdom.

Charis Ringland (C)

Roskamp Institute, Sarasota, FL, United States.
The Open University, Milton Keynes, United Kingdom.

Anastasia Edsell (A)

Roskamp Institute, Sarasota, FL, United States.

Michael Mullan (M)

Roskamp Institute, Sarasota, FL, United States.
The Open University, Milton Keynes, United Kingdom.

Fiona Crawford (F)

Roskamp Institute, Sarasota, FL, United States.
James A. Haley Veterans' Hospital, Tampa, FL, United States.
The Open University, Milton Keynes, United Kingdom.

Corbin Bachmeier (C)

Roskamp Institute, Sarasota, FL, United States.
The Open University, Milton Keynes, United Kingdom.
Bay Pines VA Healthcare System, Bay Pines, FL, United States.

Classifications MeSH